Cronos Group (CRON) Q3 2024 earnings summary

Executive summary

• Achieved record consolidated net revenue of $34.3 million in Q3 2024, up 38% year-over-year, driven by strong flower and extract sales in Canada, Israel, and international markets.

• Spinach became the top cannabis brand in Canada, leading in edibles and flower, while Peace Naturals maintained a leading position in Israel.

• Consolidated Growco (Cronos GrowCo), strengthening the supply chain and enabling further international expansion.

• Expanded Growco facility with a $51 million credit facility, consolidating Growco's results and gaining majority board control.

• Strong balance sheet with $862 million in cash and cash equivalents, positioning for future growth and market entry.

Financial highlights

• Net revenue excluding Growco was $30 million, up 21% year-over-year; Growco contributed $4.3 million.

• Adjusted Gross Profit was $10.7 million, up 170% year-over-year; Adjusted Gross Margin was 31%, up 15 percentage points.

• Net income was $7.3 million, compared to a net loss of $1.6 million in Q3 2023.

• Adjusted EBITDA was negative $6 million, a $9.2 million or 60% improvement from the prior year.

• Positive cash flow from operations of $11.6 million and free cash flow of $5 million, both significant improvements year-over-year.

Outlook and guidance

• Tracking toward the high end of $5–$10 million in OpEx savings for 2024 on a standalone basis, though Growco consolidation will offset some savings next year.

• Expect increased CapEx levels due to Growco phase two expansion, with total CapEx for the project around $51 million, to be completed by mid-year.

• Focus remains on cost savings, innovation, and expanding into new legal markets, with anticipated demand growth in Canada, Israel, and Europe.